Insulin Receptor Substrate 1 (IRS1) (pSer636) antibody

Details for Product No. ABIN362277
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms HIRS-1, G972R, IRS-1, IRS1IRM, irs1, irsu, IRS1
Epitope
pSer636
(41), (39), (38), (36), (23), (18), (17), (17), (16), (14), (13), (13), (12), (12), (12), (12), (8), (6), (6), (5), (4), (4), (4), (4), (4), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine), Rat (Rattus)
(451), (359), (340), (132), (120), (97), (75), (36), (1)
Host
Rabbit
(461), (14)
Clonality
Polyclonal
Conjugate
Un-conjugated
(13), (12), (12), (12), (12), (12), (12), (12), (12), (12), (12)
Application
Western Blotting (WB), Immunohistochemistry (IHC)
(267), (168), (145), (120), (97), (76), (47), (20), (2), (1), (1)
Pubmed 4 references available
Catalog no. ABIN362277
Quantity 50 µL
Price
198.00 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Peptide sequence around phosphorylation site of pSer636 (P-M-S (p) -P-K) derived from Human IRS-1. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.
Isotype IgG
Specificity The antibody detects endogenous level of total IRS-1 protein.
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
Alternative Name IRS-1
Background May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit
Molecular Weight 180 kDa
NCBI Accession NP_005535
UniProt P35568
Application Notes Western blotting: 1:500-1:1000
Immunohistochemistry: 1:50-1:100
Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
Background publications Szanto, Kahn: "Selective interaction between leptin and insulin signaling pathways in a hepatic cell line." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, Issue 5, pp. 2355-60, 2000 (PubMed).

Kadowaki: "Insights into insulin resistance and type 2 diabetes from knockout mouse models." in: The Journal of clinical investigation, Vol. 106, Issue 4, pp. 459-65, 2000 (PubMed).

Ozes, Akca, Mayo et al.: "A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, Issue 8, pp. 4640-5, 2001 (PubMed).

Tzatsos, Kandror: "Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation." in: Molecular and cellular biology, Vol. 26, Issue 1, pp. 63-76, 2005 (PubMed).

Hosts (461), (14)
Reactivities (451), (359), (340), (132), (120), (97), (75), (36), (1)
Applications (267), (168), (145), (120), (97), (76), (47), (20), (2), (1), (1)
Conjugates (13), (12), (12), (12), (12), (12), (12), (12), (12), (12), (12)
Epitopes (41), (39), (38), (36), (23), (18), (17), (17), (16), (14), (13), (13), (12), (12), (12), (12), (8), (6), (6), (5), (4), (4), (4), (4), (4), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top